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Fiber, butyrate and colon cancer 
Studies relating diet to oncogenesis suggest a correlation 
between fiber intake and the occurrence of colorectal cancer 
(for reviews see [l]). Experiments focusing on the role of 
dietary fiber in colonic homeostasis indicate the importance 
of fiber-derived fermentation products produced by anaero- 
bic microflora within the lumen of the large intestine [l]. In 
particular, the microbial production of a short-chain fatty 
acid, butyric acid, appears to be important for proper epithe- 
lial cell regulation [l]. Unfortunately, attempts to determine 
precisely the connection between fiber, butyrate and colon 
cancer have been complicated by the experimental chal- 
lenges inherent in studying whole organisms and the inabil- 
ity to reproduce in aivo conditions accurately in tissue 
culture. Butyrate serves as a primary energy source for 
colonocytes [l], and numerous studies on human biopsies 
and animal subjects indicate that butyrate has a proliferative 
effect on normal colonic epithelium (reviewed in [l]). Nev- 
ertheless, butyrate has anti-proliferative and differentiation- 
inducing effects on various human colon carcinoma cell 
lines, as well as on other normal and neoplastic cells, at the 
physiological (millimolar) concentrations obtained in Z&JO 
[l-3]. Despite the apparent discrepancy between in viva and 
in vitro studies, the anti-growth activity of butyrate on tissue- 
culture cells has led to the hypothesis that butyrate protects 
against colon cancer by promoting differentiation, cell-cycle 
arrest and apoptosis of transformed colonocytes [l]. 
The treatment of mammalian cells Zn &ro with low milli- 
molar concentrations of butyrate causes pleiotropic effects 
on cellular physiology, including changes in the cell mem- 
brane, the cytoskeleton, the cell cycle and gene transcrip- 
tion [4]. At least part of the effects induced by butyrate can 
be attributed to the direct inhibition of the enzyme histone 
deacetylase (HDAC) [S]. Reversible acetylation of the E- 
amino groups of lysine residues on the amino-terminal 
domains of histones is important for nucleosome assembly, 
chromatin structure and transcriptional regulation (for 
reviews see [6-S]). Although the precise mechanism(s) and 
downstream effects of histone acetylation are poorly under- 
stood, a hallmark of HDAC inhibition is cell-cycle arrest and 
the induction of cellular differentiation (reviewed in [9]). 
The possibility that butyrate-mediated inhibition of 
HDAC is, in part, responsible for the effects seen on cells 
in vitro is supported by studies using other HDAC 
inhibitors that mimic the cytological effects of butyrate. 
The inhibitors, which are microbial metabolites, were ini- 
tially identified by their ability to revert oncogenic tumor 
cells to a normal, detransformed morphology (reviewed in 
[9]). The insightful observation that one of these de- 
transforming agents, trichostatin A (TSA), was in fact a 
highly potent (nanomolar Ki) inhibitor of an HDAC activity 
in vitro and an inducer of histone hyperacetylation in &a 
paved the way for the discovery of a variety of natural prod- 
ucts with HDAC-inhibitory properties (Figure 1) [9-121. 
These findings also led to the purification and cloning of 
HDACl using the HDAC inhibitor trapoxin B (TPX) as a 
molecular probe [13]. These and subsequent studies using 
HDAC inhibitors indicated a role for HDAC in control of 
the Gl/S and G’2/M transitions of the cell cycle, as well as 
in cellular differentiation and senescence [9,14]. 
The recent demonstration that histone acetyltransferases 
(HATS) and HDACs are transcriptional regulators [6,8,15,16] 
provides evidence to support the argument that cytological 
changes induced by HDAC inhibitors are the downstream 
effects of altered transcription. In general, HDAC 
inhibitors specifically upregulate or downregulate the tran- 
scription of genes linked to cell proliferation and differenti- 
ation, such as myc [6,17-19],fos [17], and the gene encoding 
gelsolin [9], rather than altering the transcription of house- 
keeping or constitutive genes, such as the gene encoding 
GAPDH (see [6] and references therein). The effects of 
deacetylase inhibitors on cellular processes vary depending 
on the cell type and the micro-environment of the cell. In 
the colon, butyrate has the capacity to act as a signaling 
molecule, being able to traverse the cell membrane of 
colonocytes, bind to its cognate receptor HDAC, and 
mediate effects on gene transcription, resulting in dynamic 
changes in cell physiology. 
Induction of p21 by histone deacetylase inhibitors 
Among the genes that are directly transcriptionally upregu- 
lated in cells treated with butyrate or other HDAC 
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Figure 1 
Histone deacetylase inhibitors. Several natural 
products have recently been shown to inhibit 
the enzymatic activity of HDAC. The small 
organic molecules vary dramatically in their 
chemical structure. The simplest compound, 
butyric acid, is a short-chain fatty acid with an 
HDAC inhibitory Ki in the low millimolar range 
(-2 mM). Trichostatin A (TSA) and trapoxin B 
(TPX) were identified as fungal antibiotics with 
potent differentiation-inducing properties 191. 
TSA, TPX and trapoxin-related compounds 
inhibit HDAC potently at low nanomolar 
concentrations. TSA is a hydroxamic acid that 
is not structurally related to the family of 
trapoxin-related compounds. Trapoxin-related 
compounds are cyclic tetrapeptides containing 
an extended aliphatic sidechain that is required 
for biological activity and usually contains an 
epoxyketone (epok) moiety. Apparently each of 
these compounds possesses a lysine 
sidechain mimic that potentially interacts with 
the catalytic elements of the enzyme. Aib, 
a-aminoisobutyric acid; Pip, pipecolic acid. 
-kH _ 
Butyric acid Trichostatin A Trapoxin B 
Trapoxin-related cyclic tetrapeptides 
, ~I, ~~ 
Chemistrv & Bioloa\ 
inhibitors is the cyclin-dependent kinase (CDK) inhibitor 
pZl/Cipl/WAFl [20,21]. Cyclin-CDK complexes phos- 
phorylate key proteins involved in cell-cycle checkpoints 
and the DNA-replication machinery, thereby facilitating 
cell-cycle progression. The regulated formation of active 
cyclin-CDK complexes is governed principally by CDK 
inhibitors (CKIs; for review see [ZZ]). The CKI ~21 binds 
and inhibits a range of cyclin-CDK enzyme complexes in 
addition to directly associating with proliferating cell 
nuclear antigen (PCNA) and inhibiting PCNA-dependent 
DNA replication in vitro [22,23]. Transcription of ~‘21 is 
controlled by multiple factors including a p53-dependent 
mechanism induced by DNA damage [22,24] and a TGFP- 
mediated mechanism [ZS]. In addition, ~21 message levels 
are elevated by numerous differentiating agents including 
phorbol ester, dimethylsulfoxide, all trans-retinoic acid and 
vitamin D (1,25-dihydroxyvitamin Dj), implicating ~21 in 
cellular differentiation [E&21,25-271. 
The effect of butyrate and other HDAC inhibitors on cells 
is closely paralleled by the effects of ~‘21 expression. 
Studies indicate a role for ~‘21 in the regulation of the Gl 
[ZZ], S [Z&29] and G2 [Z&30,31] phases of the cell cycle. 
Furthermore, the formation of polyploid nuclei in hepato- 
cytes overexpressing ~21 [31] is reminiscent of the 
butyrate-induced polyploidism observed in certain mam- 
malian cell lines in vitro [32]. Finally, senescent cells 
demonstrate a failure to downregulate ~21 mRNA, indicat- 
ing a role for ~21 in establishing and/or maintaining senes- 
cence [33]. Given the prominent role of ~21 in cell-cycle 
control and cellular differentiation, and the phenotypic 
similarities between pZ1 induction and HDAC inhibition, 
it is possible that direct upregulation of ~21 is primarily 
responsible for the cytological effects of HDAC inhibitors. 
The abundance of naturally occurring HDAC inhibitors 
and their ability to disrupt the transcription of cell-cycle- 
specific genes suggest a convergence of microbial evolu- 
tion towards a common cellular target, HDAC, and 
emphasize the importance of this enzyme in the cell cycle 
and cellular differentiation. Potentially, combinatorial 
chemistry could be used to identify novel HDAC 
inhibitors for use in the study of histone acetylation and for 
use as possible drugs in the treatment of certain cancers. 
Direct regulation of p21 transcription by histone deacetylase 
Butyrate rapidly induces ~21 mRNA within 3 hours of 
treatment, even in the presence of protein-synthesis 
inhibitors [ZO]. These results, combined with the demon- 
stration that TPX induces ~21 [34], strongly argue that 
~21 transcription is directly repressed by HDAC. 
Although the mechanism(s) by which histone acetylation 
affects transcription remains unresolved, experiments in 
vitro suggest that transcription factors gain increased 
accessibility to their DNA-binding sites on acetylated 
templates [6,15]. In the case of the ~21 promoter, this 
implies that transcription factors capable of activating 
~‘21 transcription are present in the nucleus but have a 
reduced affinity for their DNA-binding sites when the 
local chromatin environment is deacetylated. Treatment 
with HDAC inhibitors shifts the equilibrium in the 
direction of acetylation, resulting in the binding of tran- 
scriptional activators and the subsequent production of 
~‘21 mRNA. 
HDACs might regulate transcription either by globally 
deacetylating histones or by targeting deacetylation to 
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specific gene regulatory elements. In either case, only 
genes with regulatory elements sensitive to acetylation 
will be affected. Evidence for both mechanisms exists and 
the two models need not be mutually exclusive. On the 
one hand, HDAC inhibitors cause a detectable increase in 
total cellular histone acetylation states, reaching significant 
levels in approximately 8 hours of drug treatment [35], 
which seems to indicate that a large percentage of nucleo- 
somal histones are normally deacetylated by a mechanism 
that does not require DNA replication or de nova nucleo- 
some assembly. The quantity of cellular histones becoming 
hyperacetylated argues for a global non-targeted mecha- 
nism. On the other hand, recent experiments demonstrate 
a physical link between HDACs and other known tran- 
scriptional regulators and co-repressors that either bind 
DNA directly or are associated with DNA-binding proteins 
(for review see [6]). HDACZ (mRPD3) was identified by 
Seto and colleagues [36] as a YYl-interacting protein. YY1 
(Yin Yang 1) is a zinc-finger-containing DNA-binding tran- 
scription factor that represses or activates transcription 
depending on promoter context [37]. Virtually all genes 
regulated by YYl are associated with cell growth, differen- 
tiation or development [37]. Multiple mechanisms for YYl- 
regulated transcription have been proposed, including 
those that rely on the ability of YYl to associate with coac- 
tivator and corepressor proteins (for review see [37]). Over- 
expression of HDACZ enhances YYl-mediated repression 
of a reporter gene containing YYl-binding sites and 
HDACZ is capable of autonomous repression when fused 
to a GAL4 DNA-binding domain [36]. These findings 
suggest that HDAC might be targeted to specific promoter 
or enhancer regions by Wl to regulate the transcriptional 
activity of genes through localized histone deacetylation. 
A potential Wl-binding site in the p21 promoter 
Given that HDAC inhibitors upregulate p21 transcription 
directly, it is possible for HDACs to be targeted to ~‘21 
promoter elements by specific HDAC-associated DNA- 
binding transcription factors, such as YYl. Interestingly, 
we have identified a putative YYl-binding site in the pro- 
moter of the ~21 gene (Figure Za). A combination of in 
viva and in vitro experiments have elucidated the binding- 
site selection characteristics of YYl [37]. A high affinity 
YYl-binding core motif, ACAT, is recognized by YYl 
when this site is surrounded by flanking nucleotides 
showing a certain degree of variability [37]. The 
nucleotide sequence, 5’-GGACATTGA-3’, on the anti- 
sense strand of the ~21 promoter at position -767 to -759, 
complies with the requirements of a YYl-binding site. 
The p21 gene is also regulated by the hormonal form of 
vitamin D, resulting in terminal differentiation of myeloid 
leukemia U937 cells [27]. The vitamin D-responsive 
element (VDRE) is composed of two direct repeats sepa- 
rated by a three nucleotide spacer (DR-3). The proposed 
Wl-binding site overlaps with the 3’ end of the downstream 
VDRE direct repeat (Figure Za). The liganded vitamin D 
receptor (VDR) binds to the downstream direct repeat in 
association with its heterodimeric partner, retinoid-x- 
receptor (RXR), which occupies the upstream direct repeat 
[27]. It is possible that YYl represses the ~21 promoter by 
replacing VDR on the downstream half-element of the 
VDRE in the absence of vitamin D. Experimental evi- 
dence for a YYl DNA-binding displacement model exists 
for numerous promoters [37]. In particular, displacement of 
VDR by YYl has been demonstrated in the case of the 
osteocalcin gene, a bone-specific calcium-binding protein 
expressed only in differentiated osteoblasts [38]. The simi- 
larities between the p21 gene and the osteocalcin gene 
VDRE/YYl elements are striking. ‘Both are DR-3 elements, 
as expected for vitamin-D-responsive genes, and the posi- 
tion of the putative YYl-binding site in the ~21 promoter 
overlaps the 3’ portion of the downstream direct repeat, 
mimicking the position of the established YYl-binding site 
in the osteocalcin promoter (Figure Zb). The principal dif- 
ference between the two VDREjYYl sites is that the YYl 
site in the p21 promoter is in the opposite orientation to 
that seen in the osteocalcin gene. Experiments demonstrat- 
ing that YYl can bind to the ~21 promoter and demonstrat- 
ing the ability of YYl to repress p21 transcription in an 
HDAC inhibitor-dependent fashion can be performed to 
support a functional role for YYl in p21 transcription. 
Analysis of another vitamin-D-responsive gene, calbindin- 
D2skD, reveals the presence of a partially conserved YYl- 
binding site in this promoter as well (Figure Zb). In a similar 
fashion to the p21 and osteocalcin promoters, the putative 
YYl site, 5’-ACTCA?TTC-3’ partially overlaps the down- 
stream half-site of the reported VDRE (Figure Zb). Notably, 
calbindin-D2skl, is induced by butyrate, and the butyrate- 
response element (BRE) has been mapped to a region 
directly downstream of the proposed YYl-binding site [39]. 
Curiously, a transiently transfected construct containing the 
BRE but lacking the YYl site retains butyrate inducibility 
following prolonged drug treatment [39], suggesting that 
the BRE is still deacetylated in the absence of the 
VDRE/YYl element. Related BREs have been found in 
several butyrate-sensitive and HDAC-inhibitor-sensitive 
promoters [39,40] (Figure Zb). No regions of the p21 pro- 
moter show significant homology to the calbindin-DZsk,, 
BRE, although transient transfection experiments implicate 
two Spl-binding sites near the TATA box (nucleotides -101 
to -77) as being important for activation by butyrate [ZO]. 
These mapping experiments suggest that a promoter 
lacking the putative YYl-binding site retains sensitivity to 
butyrate. Unlike the native p21 gene, however, which is 
strongly induced by butyrate within 3 hours, recombinant 
reporter genes containing truncated forms of the p21 pro- 
moter require significantly longer time periods of butyrate 
treatment before showing detectable levels of induction 
[ZO]. The discrepancy in the time courses may reflect the 
potential problems associated with studying chromatin 
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regulation in artificial transcription systems. It will be neces- 
sary to study the native ~21 promoter in its natural chro- 
matin context to ascertain the involvement of p2 1 regulatory 
elements in maintaining particular acetylation states. 
The conserved architecture of the native ~21, osteocalcin 
and calbindin-D,,,, VDRE/YYl promoter elements sug- 
gests the potential for a related mechanism of transcrip- 
tional regulation in which certain vitamin-D-responsive 
genes recruit YYl and an associated HDAC to enhance 
transcriptional silencing. The system described here 
provides two independent signaling mechanisms for 
altering transcription of the pZ1 gene. In one case 
1,25-dihydroxyvitamin D, binds to the VDR, thereby 
facilitating the binding of VDR to DNA and the sub- 
sequent transcriptional activation of ~21. In the other 
case, butyrate binds to a targeted HDAC and inhibits 
its transcriptional repression function, leading to ~21 
Figure 2 
transcription. The similarities of these small molecule- 
dependent signaling pathways are shown in Figure 3. We 
have compiled the available data and note an intriguing 
correlation between WI-regulated genes and sensitivity 
to HDAC inhibitors (Table 1). Genes repressed by YYl 
are activated by deacetylase inhibitors, whereas genes 
activated by YY1, such as cyc.kz DI, are downregulated by 
HDAC inhibitors. This is consistent with both a positive 
and a negative role for HDACs in transcription (for 
review see [6,9,15]). Not all promoters affected by 
deacetylase inhibitors contain both a YYl-binding site 
and a VDRE, however, and further experiments are war- 
ranted in order to determine the generality of these 
observations and the precise role for each component 
involved. More recent advances in transcript-array tech- 
nology might aid in the identification of genes transcrip- 
tionally altered by HDAC inhibitors and might also 
provide a method of determining potential differences in 
- 
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(a) A putative YYl -binding site in the cyclin-dependent kinase inhibitor 
p21 promoter. Several transcriptional regulatory elements have been 
identified in the promoter/enhancer regions upstream of the ~21 
transcription start site. These elements include a DNA-damage- 
responsive p53-binding site [22,24] and a transforming growth factor b 
(TGF-b) responsive element [251. The p21 promoter also contains a 
DR-3 type (direct repeat spaced by 3 nucleotides) vitamin D-responsive 
element (VDRE) [27] which is underlined. In the presence of vitamin D 
(1,25 dihydroxy vitamin Ds), a liganded vitamin D receptor (VDR) 
heterodimerizes with the retinoid X receptor (RXR). The VDR-RXR 
heterodimer binds to the VDRE as indicated. A putative ACAT-motif 
YYl -binding site is highlighted in red on the antisense strand. This site 
consists of a core CAT YY 1 -binding sequence flanked by a variable 
consensus sequence. The YYl site overlaps the downstream direct 
repeat of the VDRE, possibly allowing competitive binding between 
YYl and RXRIVDR for the DNA-regulatory site. (b) Alignment of the 
osteocalcin and calbindin-D sskD promoters with the ~21 promoter. 
Transcription of both the osteocalcin and calbindin-D,sko genes is 
induced by vitamin D and their VDRE elements are shown underlined. 
Both genes also contain a consensus YYl -binding site (putative in the 
case of calbindin-D,,,,) shown in red overlapping the downstream 
direct repeat VDR-binding site either on the sense strand (osteocalcin) 
or the antisense strand (calbindin-D,,,,). YYl has been shown to 
compete with VDR/RXR heterodimers for binding to the osteocalcin 
promoter VDRE [38]. Unlike the p21 and osteocalcin promoters, both 
of which contain DR-3 VDREs, calbindin-Dssko contains a DR-4 site 
[391. The effects of these differences in the DNA-binding sites and in 
orientation of the YYl -binding site on transcription are unknown. 
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HDAC-inhibitor specificities. For example, the HDAC 
family members may regulate different genes allowing 
for the possibility of inhibitors that affect only a subset of 
HDAC-regulated genes, similar to the differential effects 
mediated by steroid hormones in transcription. 
Interpretation of data derived from HDAC inhibitor studies 
is complicated by the possibility of indirect transcriptional 
Figure 3 
effects caused by hyperacetylation. Furthermore, not all 
genes directly influenced by HDACs will require YY1, nor 
is YY1 necessarily acting alone in recruiting HDACs. 
HDACs are thought to associate with the nuclear co-repres- 
sor, N-CoR, and the related SMRT (silencing mediator of 
retinoid and thyroid hormone receptors) proteins, as well as 
with the mSin3 co-repressor, to form a multi-protein tran- 
scriptional regulatory complex. Evidence suggests that 
(a) 
leads to transcriptional derepression 
No p21 transcription ~21 transcription 
Displacement of 
YYl IH DAC 
No p21 transcription p21 transcription 
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A model for transcriptional regulation of the cyclin-dependent kinase 
inhibitor p2l /Cipl /WAFl by a VDREIYYl regulatory element in the 
p21 promoter. Two independent small molecule-mediated signaling 
pathways may affect the transcriptional response of the p21 gene in 
colonocytes. A schematic representation of a colon cell is shown 
(cytoplasm in gray and nucleus in yellow). Both butyrate (a) and the 
hormonal form of vitamin D (b) can traverse the plasma and nuclear 
membranes and bind their intracellular receptors causing changes in 
transcription that result in cell-cycle arrest and differentiation 
(represented as a change in cellular morphology). Vitamin D binds the 
vitamin D receptor (VDR; purple) and butyrate binds HDAC (red). A 
putative YYl -binding site in the p21 promoter is occupied by YYl 
under non-inducing conditions (DNA is shown in blue). YYl represses 
transcription, in part through association with the co-repressor HDAC. 
HDAC may mediate localized deacetylation of nucleosomal histones, 
shown here as red cylinders when deacetylated and green cylinders 
when acetylated. Derepression of p21 transcription can occur in two 
ways, either (a) through the inhibition of HDAC by butyrate, a short- 
chain fatty acid produced by colonic bacteria during the fermentation 
of certain forms of dietary fiber, or (b) through VDR-mediated activation 
via the ligand-dependent association of VDR with its heterodimeric 
DNA-binding partner RXR (retinoid X receptor; orange) which binds to 
the VDRE and subsequently recruits a transcriptional coactivator 
complex. This complex may include the coactivator/HAT N-CoA (dark 
green), also known as steroid receptor coactivator (SRCl), and/or 
CREB-binding protein (CBP) or the related protein ~300 (dark pink), 
as well as the associated coactivator/HATs PCAF (dark blue) and 
PCIP (light pink). YYl may also activate transcription through direct 
association with ~300 [41], although it is not known whether HDAC 
and ~300 associate with YYl simultaneously. 
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Table 1 
Summary of HDAC inhibitor effects on various genes and their relationship to transcriptional regulation by YYl. 
Transcript (gene) 
YYl regulation 
Binding site YYl effect 
Deacetylase inhibitor response 
Inhibitors tested Response Direct effect? 
Vitamin D response 
VDRE site Response 
calbindin* Y** I Butyrate 7‘ N/A Y t 
osteocalcint Y 1 N/A -r++ N/A Y T 
p2llwafl* Y** 1 Butyrate, TPX t Y Y -r 
cyclin D 15 Y** 1‘ Butyrate L Y 
c-f0.F Y J Butyrate, TSA t Y 
p-glycoprotein (MDRI)( Y** 1 Butyrate T N/A 
metallothioneir? Y** 1 Butyrate 7 N/A GRE ? 
The genes listed were generally selected because their mRNA levels shown to be directly induced by butyrate and is also trapoxin-inducible 
are modulated by HDAC inhibitors in a direct fashion and they contain [20,34]. §A putative YYl site in the cyclin D7 promoter is located at 
consensus YYI -binding sites in their promoters, The promoter of the -748/-742 (Genbank number LO9054) [43]. #Nucleotides -63/-54 
gene listed either contains a confirmed or putative (**) YY 1 -binding of the c-fos promoter have been shown to be the target of butyrate- 
site (Y indicates that the gene contains a site). Transcriptional mediated induction of c-fos transcription [441. This same site has been 
repression is indicated by 1 and activation is indicated by 1‘ shown to contain binding sites for YYl and cyclic-AMP-response 
(*predicted, depending on whether or not the gene contains a binding protein (CREB) [451. CREB associates with CREB-binding 
confirmed YYl-binding site). A subset of genes also induced by protein (CBP) which is reported to be a histone acetyltransferase 
vitamin D and defined VDRE (vitamin D response element) sites are 115,161. nA consensus YYl site, corresponding to a previously 
noted. In the case of the metallothionein gene, a glucocorticoid mapped repressive element [46], is found -368/-360 upstream of the 
response element (GRE), rather than a VDRE, overlaps the YYl site MDR7 transcription start site (Genbank number X58723). Butyrate 
[42]. Most genes listed are activated through the inhibition of HDAC, upregulates transcription of MDRl [47]. YTranscription of 
but cyclin DI is transcriptionally downregulated directly by HDAC metallothionein is induced by butyrate [42]. A consensus YYl site is 
inhibitors [43]. N/A, data not available; TSA, trichostatin A; TPX, found on the antisense strand from nucleotides -240/-230 (Genbank 
trapoxin (see Figure 1). *See Figure 2b and [39], (Genbank number number D10551). This region overlaps a glucocorticoid response 
L11891). +For an analysis of the YYl/VDRE sites see [38]. *See element (GRE; -245/-231) [48] providing the possibility for 
Figure 2a,b and [27], (Genbank number U24170); p21 has been glucocorticoid receptor-mediated displacement of YY 1. 
these macromolecular complexes are recruited by nuclear 
receptors and by the Mad family of E-box DNA-binding 
transcription factors [6,15]. Interestingly, YY1 associates 
with the coactivator ~300 [41], which has recently been 
shown to possess both an associated and an intrinsic HAT 
activity [15,16]. YYl might therefore indirectly mediate 
both acetylation and deacetylation at certain promoters. It is 
unknown if YYl associates with both ~300 and HDAC 
simultaneously. Whether cells not expressing p21 will be 
affected by deacetylase inhibitors remains to be tested. 
Conclusions and prospects 
The potential anti-colon-cancer properties of fiber can be 
linked to a small-molecule signaling pathway involving 
butyrate, a by-product of fiber-metabolizing bacteria within 
the colon, and its cellular target HDAC. Butyrate inhibits 
the enzymatic activity of HDAC, resulting in changes in 
the transcription of specific genes, including the induction 
of the cyclin-dependent kinase inhibitor pZl/Cipl/WAFl. 
Both inhibition of HDAC and expression of pZ1 result in 
cell-cycle arrest and differentiation, suggesting that induc- 
tion of p21 is a pivotal event in HDAC inhibitor-mediated 
cell-cycle arrest. Experiments suggest that both targeted 
and non-targeted deacetylation of the ~21 promoter by 
HDAC may be important for the transcriptional repression 
of ~21. We speculate that the DNA-binding transcription 
factor YYl negatively regulates ~21 in part by recruiting 
HDAC to a proposed YYl-binding site in the promoter of 
the pZ1 gene. Butyrate may therefore alleviate repression 
of pZ1 by inhibiting a YYl-targeted HDAC. The mecha- 
nism is similar to that used by steroid hormones in activat- 
ing signaling pathways that lead to modified transcription 
of target genes. In both cases, a membrane-permeable 
small molecule binds to a protein involved in targeted gene 
regulation, thus altering the transcription of specific genes. 
The further study of the mechanism of HDAC inhibitor- 
mediated cell-cycle arrest could lead to the design of other 
potent small-molecule HDAC inhibitors with potential 
application in colon-cancer therapies. 
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